Recombinant human plasma gelsolin (rhu-pGSN) in a patient hospitalized with critical COVID-19 pneumonia
Related Experiment Video
Updated: Oct 24, 2025
08:53
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
Published on: March 28, 2025
561
Julie V Catteeuw1, Mark J DiNubile2
1Jan Palfijn, Gent, Belgium.
Clinical Infection in Practice
|August 16, 2021
Abstract:
Life-threatening COVID-19 pneumonia follows an exaggerated immune response to SARS-CoV-2. pGSN levels fall after SARS-CoV-2 infection. Rhu-pGSN improves outcomes in models of inflammation. In an intubated patient with critical COVID-19 pneumonia and progressive hypoxemia despite standard care, improvement became evident during rhu-pGSN infusions with full recovery within a few weeks.
